Gunnar Kvalheim

Oslo, Norway

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 56 publications

Production of mRNA-Loaded Dendritic Cell Cancer Vaccines.

Production of mRNA-Loaded Dendritic Cell Cancer Vaccines.

Journal: Methods in molecular biology (Clifton, N.J.)
Published: August 28, 2025

Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16.

Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16.

Journal: Journal for immunotherapy of cancer
Published: March 08, 2024

Transient TCR-based T cell therapy in a patient with advanced treatment-resistant MSI-high colorectal cancer.

Transient TCR-based T cell therapy in a patient with advanced treatment-resistant MSI-high colorectal cancer.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: January 21, 2024

CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia.

CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia.

Journal: Cell reports. Medicine
Published: October 30, 2023

WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy.

WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy.

Journal: Leukemia
Published: January 16, 2023

A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT).

A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT).

Journal: Frontiers in oncology
Published: August 29, 2022

ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma.

ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma.

Journal: Nature communications
Published: April 17, 2022

A phase I prospective, non-randomized trial of autologous dendritic cell-based cryoimmunotherapy in patients with metastatic castration-resistant prostate cancer.

A phase I prospective, non-randomized trial of autologous dendritic cell-based cryoimmunotherapy in patients with metastatic castration-resistant prostate cancer.

Journal: Cancer immunology, immunotherapy : CII
Published: March 12, 2022

Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy.

Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy.

Journal: The Prostate
Published: July 12, 2021

Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors.

Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors.

Journal: Oncoimmunology
Published: July 08, 2021

Combinatorial CAR design improves target restriction.

Combinatorial CAR design improves target restriction.

Journal: The Journal of biological chemistry
Published: October 09, 2020

Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy.

Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: June 16, 2020
Showing 1-12 of 56

Last Updated: 09/26/2026